These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

148 related items for PubMed ID: 335094

  • 1. Treatment of Parkinson's disease with lergotrile mesylate.
    Lieberman A, Estey E, Kupersmith M, Gopinathan G, Goldstein M.
    JAMA; 1977 Nov 28; 238(22):2380-2. PubMed ID: 335094
    [Abstract] [Full Text] [Related]

  • 2. Treatment of parkinson's disease with bromocriptine.
    Lieberman A, Kupersmith M, Estey E, Goldstein M.
    N Engl J Med; 1976 Dec 16; 295(25):1400-4. PubMed ID: 989885
    [Abstract] [Full Text] [Related]

  • 3. Lergotrile in Parkinson disease: further studies.
    Lieberman AN, Gopinathan G, Estey E, Kupersmith M, Goodgold A, Goldstein M.
    Neurology; 1979 Feb 16; 29(2):267-72. PubMed ID: 34808
    [Abstract] [Full Text] [Related]

  • 4. Comparison between lergotrile and bromocriptine in parkinsonism.
    Teychenne PF, Pfeiffer RF, Bern SM, McInturff D, Calne DB.
    Ann Neurol; 1978 Apr 16; 3(4):319-24. PubMed ID: 666273
    [Abstract] [Full Text] [Related]

  • 5. Bromocriptine, lergotrile: the antiparkinsonian efficacy and the interaction with monoaminergic receptors.
    Goldstein M, Lieberman A, Battista AF, Lew JY, Hata F.
    Pharmacology; 1978 Apr 16; 16 Suppl 1():143-9. PubMed ID: 25445
    [Abstract] [Full Text] [Related]

  • 6. Treatment of Parkinson's disease with dopamine agonists: a review.
    Lieberman A, Neophytides A, Kupersmith M, Casson I, Durso R, Foo SH, Khayali M, Tartaro T, Goldstein M.
    Am J Med Sci; 1979 Apr 16; 278(1):65-76. PubMed ID: 39452
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. The effects of combining carbidopa with levodopa for Parkinson's disease.
    Martin WE, Tolosa ES, Loewenson RB, Lee MC, Resch JA, Baker AB.
    Geriatrics; 1975 Dec 16; 30(12):39-44. PubMed ID: 1104406
    [No Abstract] [Full Text] [Related]

  • 15. [Lisuride in the combination treatment of Parkinson disease].
    Jellinger K.
    Wien Med Wochenschr; 1987 Apr 30; 137(7-8):155-9. PubMed ID: 3111099
    [Abstract] [Full Text] [Related]

  • 16. A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson's disease.
    Olanow CW, Fahn S, Muenter M, Klawans H, Hurtig H, Stern M, Shoulson I, Kurlan R, Grimes JD, Jankovic J.
    Mov Disord; 1994 Jan 30; 9(1):40-7. PubMed ID: 8139604
    [Abstract] [Full Text] [Related]

  • 17. Switching from ergot to nonergot dopamine agonists in Parkinson's disease: a clinical series and five-drug dose conversion table.
    Grosset K, Needleman F, Macphee G, Grosset D.
    Mov Disord; 2004 Nov 30; 19(11):1370-4. PubMed ID: 15389984
    [Abstract] [Full Text] [Related]

  • 18. Treatment of Parkinson's disease with 8-alpha-amino-ergoline, CU 32-085.
    Schneider E, Hubener K, Fischer PA.
    Neurology; 1983 Apr 30; 33(4):468-72. PubMed ID: 6682193
    [Abstract] [Full Text] [Related]

  • 19. Dopaminephilic properties of ergot alkaloids.
    Goldstein M, Lew JY, Nakamura S, Battista AF, Lieberman A, Fuxe K.
    Fed Proc; 1978 Jun 30; 37(8):2202-6. PubMed ID: 26607
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.